Peginterferon beta-1a
Also known as: BG00012, IFN beta-1a (PEGylated), PEG-IFN beta-1a, PEG‑IFN beta‑1a, Pegylated interferon beta‑1a, Plegridy
Source Peginterferon beta-1a at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Peginterferon beta-1a (Plegridy) is a PEGylated form of interferon‑beta‑1a approved as a disease‑modifying therapy for adults with relapsing‑remitting multiple sclerosis (RRMS). By attaching a polyethylene glycol chain, the molecule attains a longer half‑life, allowing subcutaneous injection every two or four weeks instead of the more frequent dosing required for non‑PEG interferons.
Mechanism of Action
Peginterferon beta‑1a binds the type I interferon receptor (IFNAR) on immune cells, activating the JAK‑STAT pathway and inducing antiviral and anti‑inflammatory genes. The PEG moiety prolongs circulation, enhancing sustained receptor engagement and increasing overall biologic activity compared with native interferon‑beta‑1a. This modulation dampens autoreactive T‑cell activity and reduces inflammatory cytokine production that drive MS relapses.
What the Research Shows
The pivotal ADVANCE phase III trial enrolled RRMS patients and compared subcutaneous peginterferon beta‑1a (125 µg) given every 2 weeks or every 4 weeks with placebo for one year, followed by a two‑year extension. Over 96 weeks, the every‑2‑week regimen cut the adjusted annualized relapse rate by 36 % versus placebo and lowered the risk of confirmed disability progression and the number of new or enlarging T2 MRI lesions. Efficacy was maintained through two years, with greater benefit seen for the more frequent dosing schedule. Safety was comparable to established interferon‑beta products, the most frequent adverse events being injection‑site erythema and influenza‑like illness. A 2015 review confirmed these findings and noted an acceptable tolerability profile, while a 2018 analysis highlighted the absence of head‑to‑head trials and limited post‑marketing comparative data.
Reported Benefits
Clinical trials demonstrate that peginterferon beta‑1a reduces relapse frequency (approximately one‑third fewer relapses per patient‑year) and slows disability progression in RRMS. MRI outcomes show fewer new or enlarging lesions, indicating reduced disease activity. The PEGylated formulation permits dosing every two weeks, which may improve patient adherence compared with more frequent non‑PEG interferon injections.
Limitations of the Evidence
Evidence is confined to placebo‑controlled studies; no direct comparisons with other disease‑modifying therapies have been published, leaving its relative efficacy uncertain. Long‑term data beyond two years are limited, and post‑marketing trials have not yet clarified effects on disability progression. Consequently, the precise place of peginterferon beta‑1a within MS treatment algorithms remains unclear.
Safety Considerations
The most common adverse events are mild to moderate injection‑site erythema and influenza‑like illness, mirroring the safety profile of other interferon‑beta agents. No increased risk of autoimmune disorders, depression, serious infections, or seizures was observed in trials. Transient elevations in liver enzymes can occur, as with other interferons, but clinically apparent hepatotoxicity is rare. Routine monitoring of injection reactions and liver function is advised.
How It Is Administered
Peginterferon beta‑1a is supplied for subcutaneous injection (intramuscular use is also listed) at a dose of 125 µg, typically administered every two weeks; a four‑week schedule is an alternative. The PEGylated formulation allows this reduced injection frequency compared with non‑PEG interferon‑beta products.
Routes of Administration
Goals & Uses
- Reduce relapse rate in relapsing-remitting multiple sclerosisDisease ModificationHigh
- Active secondary progressive MS managementDisease ModificationModerate
- Treatment of clinically isolated syndrome (CIS)Disease ModificationModerate
- Reduce MRI lesion burden in MSDisease ModificationHigh
- Delay disability progression in MSDisease ModificationModerate
- Reduce relapse rate and disability progression in relapsing multiple sclerosisMultiple SclerosisHigh
Contraindications
- Decompensated hepatic diseaseHepaticHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Active autoimmune disease other than MSAutoimmuneModerate
- Uncontrolled hepatic impairmentHepaticModerate
- Severe depression or active suicidal ideationPsychiatricModerate
- Hypersensitivity to interferon beta or PEGAllergyHigh
- Known hypersensitivity to natural or recombinant interferon beta, peginterferon, or any excipientAllergy/ImmunologyHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalCommon
- Injection site reactionsLocalCommon
- Leukopenia / lymphopeniaHematologicUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Elevated liver enzymes (hepatotoxicity)HepaticUncommon
- Elevated liver enzymes (ALT/AST)HepaticUncommon
- Anaphylaxis and serious allergic reactionsImmunologicRare
- Depression and suicidal ideationPsychiatricUncommon
- Injection‑site reactions (redness, pain, induration)LocalCommon
- DepressionPsychiatricUncommon
- Flu‑like syndrome (fever, chills, myalgia)SystemicCommon
- Leukopenia/lymphopeniaHematologicUncommon
Drug Interactions
- AntidepressantsLow
- Live attenuated vaccinesModerate
- Myelosuppressive agentsModerate
- CYP450 substrates (narrow therapeutic index)Low
- Hepatotoxic drugs (e.g., isoniazid, methotrexate)Moderate
- Immunosuppressive agents (e.g., azathioprine, mycophenolate)Moderate
- Hepatotoxic drugsModerate
Population Constraints
- Pre-existing psychiatric disordersPsychiatricRelative
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patients (<18 years)AgeRelative
- Pediatric patients (<18 y)AgeRelative
- Elderly patients (>65 y)AgeRelative
- Lactating womenReproductiveRelative
- Pregnant womenReproductiveAbsolute
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionApprovedApproved: relapsing forms of multiple sclerosisEMA approval; same dosing schedule.
- United StatesApprovedApproved: relapsing forms of multiple sclerosisApproved as Plegridy; subcutaneous weekly injection.
- United KingdomApprovedApproved: relapsing forms of multiple sclerosisMHRA approval; marketed under Plegridy.
FDA approved (2014) for relapsing‑remitting MS; EMA and MHRA approvals for the same indication. Marketed as Plegridy.
Evidence & Sources
- Journal ArticleModerateSimó M , Iljicsov A 2017-01-01T00:00:00.000000Z
- Journal ArticleModerateHoy SM2015-01-01T00:00:00.000000Z
- Journal ArticleModerateHoofnagle JH2012-01-01T00:00:00.000000Z
- Journal ArticleModerate2015-01-01T00:00:00.000000Z
- Journal ArticleModerateGerardi C, et al.2018-01-01T00:00:00.000000Z
Frequently Asked Questions
How does peginterferon beta‑1a differ from older interferon‑beta drugs?
Peginterferon beta‑1a is chemically linked to a polyethylene glycol chain, which extends its half‑life and permits dosing every two weeks instead of the three‑times‑weekly schedule required for non‑PEG interferons, while maintaining a similar safety profile.
What clinical benefit can patients expect from this therapy?
In controlled trials, patients experienced about a 36 % reduction in annualized relapse rate, fewer new MRI lesions, and a modest decrease in the risk of confirmed disability progression compared with placebo.
Are there any serious safety concerns with peginterferon beta‑1a?
Serious adverse events are uncommon; the most frequent issues are injection‑site redness and flu‑like symptoms, usually mild to moderate. Liver enzyme elevations can occur but rarely lead to clinically significant liver injury.
Is peginterferon beta‑1a compared directly with other MS drugs?
No head‑to‑head trials have been published, so its comparative efficacy and tolerability relative to other disease‑modifying therapies remain unestablished.
How is the medication administered?
It is given as a subcutaneous injection of 125 µg, most often every two weeks, allowing patients to avoid the more frequent injections required by earlier interferon formulations.
What is Peginterferon beta-1a?
Peginterferon beta-1a (Plegridy) is a PEGylated form of interferon‑beta‑1a approved as a disease‑modifying therapy for adults with relapsing‑remitting multiple sclerosis (RRMS). By attaching a polyethylene glycol chain, the molecule attains a longer half‑life, allowing subcutaneous injection every two or four weeks instead of the more frequent dosing required for non‑PEG interferons.
What is Peginterferon beta-1a used for?
Peginterferon beta-1a is educationally associated with: Reduce relapse rate in relapsing-remitting multiple sclerosis, Active secondary progressive MS management, Treatment of clinically isolated syndrome (CIS), Reduce MRI lesion burden in MS, Delay disability progression in MS, Reduce relapse rate and disability progression in relapsing multiple sclerosis. Educational only — not medical advice.
How is Peginterferon beta-1a administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Peginterferon beta-1a?
Reported adverse effects include: Flu-like symptoms, Injection site reactions, Leukopenia / lymphopenia, Headache, Elevated liver enzymes (hepatotoxicity), Elevated liver enzymes (ALT/AST), Anaphylaxis and serious allergic reactions, Depression and suicidal ideation, Injection‑site reactions (redness, pain, induration), Depression, Flu‑like syndrome (fever, chills, myalgia), Leukopenia/lymphopenia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Peginterferon beta-1a?
Recorded contraindications: Decompensated hepatic disease, Pregnancy, Active autoimmune disease other than MS, Uncontrolled hepatic impairment, Severe depression or active suicidal ideation, Hypersensitivity to interferon beta or PEG, Known hypersensitivity to natural or recombinant interferon beta, peginterferon, or any excipient. Consult a qualified clinician before use.